clinical trial · NCT06315608
MRG-001 in Patients With Amyotrophic Lateral Sclerosis
Amyotrophic Lateral SclerosisLou Gehrig DiseaseMotor Neuron DiseaseMotor Neuron AtrophyMRG-001
brief summary
The proposed study is an Open-Label, Single-Dose Study to Assess the Safety, and Pharmacodynamics (PD) signals of MRG-001 in Patients with Amyotrophic Lateral Sclerosis (ALS). MRG-001 will be administered subcutaneously 3 times per week for 2 weeks. This cycle will be repeated for 3 months. In total, patients are expected to receive 18 injections over the span of 3 months.
started
Jul 1, 2025
primary completion
Jan 1, 2026
completion
Mar 1, 2026
last updated
Aug 23, 2024
official title
An Open-Label, Proof of Concept Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of MRG-001 in Patients With Amyotrophic Lateral Sclerosis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol